BPI Activators
Bactericidal/Permeability-Increasing protein (BPI) activators are a distinctive set of chemical compounds that contribute to the enhancement of BPI's fundamental role in neutralizing lipopolysaccharides (LPS) of gram-negative bacteria and facilitating bacterial clearance. For instance, Zinc Pyrithione and Polymyxin B are known to disturb the bacterial outer membrane, thus augmenting BPI's accessibility to LPS and reinforcing its bactericidal impact. Similarly, EDTA chelates vital cations that maintain bacterial membrane integrity, thereby amplifying BPI's interaction with LPS and its subsequent neutralization. Moreover, compounds such as Gallic Acid and Magnesium Chloride have roles in protecting and stabilizing BPI's structure, which is crucial for its optimal functioning, especially in the hostile environments of infection where oxidative stress is prevalent.
In concert with these membrane-targeting agents, other chemicals enhance BPI's activity through synergistic effects on the immune system. For instance, Uridine-5'-Triphosphate (UTP) enhances the chemotaxis of phagocytes, potentially concentrating BPI at sites of infection. Lactoferrin's iron-sequestration ability limits bacterial propagation, reducing competition and promoting BPI's effectiveness. Magnesium Chloride and Nicotinamide are proposed to stabilize BPI structure and enhance immune function, respectively, ensuring BPI's optimal activity. The combined effects of these activators, including the antimicrobial properties of Allicin and the potentiation of bactericidal environments by Sodium Hypochlorite, create conditions that significantly bolster BPI's role in the innate immune response, establishing a fortified defense against bacterial infections.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GM 6001 | 142880-36-2 | sc-203979 sc-203979A | 1 mg 5 mg | $77.00 $270.00 | 55 | |
GM6001 is a broad-spectrum matrix metalloproteinase inhibitor. By inhibiting MMPs, it could prevent the degradation of extracellular matrix proteins, which may lead to an increased local concentration of BPI at infection sites, as it is known to bind to such proteins aiding in its antibacterial function. | ||||||
Zileuton | 111406-87-2 | sc-204417 sc-204417A sc-204417B sc-204417C | 10 mg 50 mg 1 g 75 g | $84.00 $307.00 $369.00 $1254.00 | 8 | |
Zileuton is a 5-lipoxygenase inhibitor, which may enhance BPI activity by reducing leukotriene synthesis. Leukotrienes are involved in the inflammatory response and their reduction could potentially reduce competitive binding at bacterial surfaces, allowing BPI to function more effectively in pathogen clearance. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib is a Janus kinase (JAK) inhibitor. By dampening JAK-STAT signaling, it could modulate the inflammatory response, which may lead to a more favorable environment for BPI activity by reducing protease activity that could degrade BPI. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $296.00 | 7 | |
Amiloride is a diuretic that acts as a sodium channel blocker. By reducing sodium reabsorption, it could potentially increase the pH of local environments, which may favor BPI's activity since BPI is more active at higher pH levels. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium butyrate is a short-chain fatty acid that acts as a histone deacetylase inhibitor. By modifying chromatin structure, it could enhance the expression of certain proteins, indirectly increasing the functional activity of BPI as part of the innate immune response. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 (PGE2) has varied immunomodulatory effects. By modulating the immune response, PGE2 could enhance the recruitment of neutrophils, thereby indirectly increasing the functional activity of BPI as more BPI is brought to the site of infection. | ||||||
Resolvin D1 | 872993-05-0 | sc-204877 sc-204877A | 10 µg 25 µg | $262.00 $614.00 | 1 | |
Resolvin D1 is a specialized pro-resolving mediator that can dampen the inflammatory response and promote the clearance of neutrophils from inflammatory sites. By facilitating neutrophil apoptosis and clearance, it may increase the release and local concentration of BPI, enhancing its antibacterial activity. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $55.00 $125.00 | 13 | |
Pioglitazone is a peroxisome proliferator-activated receptor gamma (PPARγ) agonist. Activation of PPARγ could lead to an anti-inflammatory effect, potentially reducing the degradation of BPI by proteases at the site of inflammation and thus maintaining its bactericidal activity. | ||||||